Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

SARS‐CoV‐2 infections in cancer outpatients - Most infected patients are asymptomatic carriers without impact on chemotherapy

 
: Hempel, L.; Piehler, A.; Pfaffl, M.W.; Molnar, J.; Kirchner, B.; Robert, Sebastian; Veloso, J.; Gandorfer, B.; Trepotec, Z.; Mederle, S.; Keim, S.; Milani, V.; Ebner, F.; Schweneker, K.; Fleischmann, B.; Kleespies, A.; Scheiber, J.; Hempel, D.; Zehn, D.

:
Fulltext urn:nbn:de:0011-n-6057142 (245 KByte PDF)
MD5 Fingerprint: bf708141c700993a1f59bc1d9a2b650b
(CC) by
Created on: 16.10.2020


Cancer medicine (2020), Online First, 9 pp.
ISSN: 2045-7634
English
Journal Article, Electronic Publication
Fraunhofer IOSB ()

Abstract
Oncologic patients are regarded as the population most at risk of developing a severe course of COVID-19 due to the fact that malignant diseases and chemotherapy often weaken the immune system. In the face of the ongoing SARS-CoV-2 pandemic, how particular patients deal with this infection remains an important question. In the period between the 15 and 26 April 2020, a total of 1227 patients were tested in one of seven oncologic outpatient clinics for SARS-CoV-2, regardless of symptoms, employing RT-qPCR. Of 1227 patients, 78 (6.4%) were tested positive of SARS-CoV-2. Only one of the patients who tested positive developed a severe form of COVID-19 with pneumonia (CURB-65 score of 2), and two patients showed mild symptoms. Fourteen of 75 asymptomatic but positively tested patients received chemotherapy or chemo-immunotherapy according to their regular therapy algorithm (±4 weeks of SARS-CoV-2 test), and 48 of 78 (61.5%) positive-tested patients received glucocorticoids as co-medication. None of the asymptomatic infected patients showed unexpected complications due to the SARS-CoV-2 infection during the cancer treatment. These data clearly contrast the view that patients with an oncologic disease are particularly vulnerable to SARS-CoV-2 and suggest that compromising therapies could be continued or started despite the ongoing pandemic. Moreover the relatively low appearance of symptoms due to COVID-19 among patients on chemotherapy and other immunosuppressive co-medication like glucocorticoids indicate that suppressing the response capacity of the immune system reduces disease severity.

: http://publica.fraunhofer.de/documents/N-605714.html